Demographic and Behavioral Risk Factors Associated with Reduced Susceptibility of Neisseria gonorrhoeae to First-Line Antimicrobials in South African Men with Gonococcal Urethral Discharge

Neisseria gonorrhoeae is the predominant cause of male urethral discharge in South Africa, and escalating prevalence of gonococcal antimicrobial resistance (AMR) is a major health concern both in-country and globally. We analyzed the demographic, behavioral, and clinical characteristics of 685 men presenting with gonococcal urethral discharge to sentinel surveillance clinics over a 3-year period (2017 to 2019) to determine the burden of factors that are known to be associated with N. gonorrhoeae AMR to first-line therapy (defined as group 1 isolates exhibiting resistance or reduced susceptibility to extended-spectrum cephalosporins or azithromycin). ABSTRACT Neisseria gonorrhoeae is the predominant cause of male urethral discharge in South Africa, and escalating prevalence of gonococcal antimicrobial resistance (AMR) is a major health concern both in-country and globally. We analyzed the demographic, behavioral, and clinical characteristics of 685 men presenting with gonococcal urethral discharge to sentinel surveillance clinics over a 3-year period (2017 to 2019) to determine the burden of factors that are known to be associated with N. gonorrhoeae AMR to first-line therapy (defined as group 1 isolates exhibiting resistance or reduced susceptibility to extended-spectrum cephalosporins or azithromycin). Among 685 men with gonococcal urethral discharge, median age was 28 years (interquartile range [IQR], 24 to 32). Only two men (2/632; 0.3%) self-identified as homosexual; however, on further enquiry, another 16 (2%) confirmed that they had sex with men only. Almost 30% practiced oral sex and were at risk for pharyngeal gonococcal infection. In univariate analysis, male circumcision (odds ratio [OR], 0.69; 95% confidence interval [CI], 0.49 to 0.99) and recent sex outside the country (OR, 1.83; 95% CI, 1.21 to 2.76) were significantly associated with having a category 1 N. gonorrhoeae isolate. In a multivariable model, only sex outside South Africa increased the odds of being infected with a decreased susceptible/resistant N. gonorrhoeae isolate (adjusted odds ratio [aOR], 1.64; 95% CI, 1.05 to 2.55). These findings warrant the intensification of N. gonorrhoeae AMR surveillance among recently arrived migrant and overseas traveler populations, as well as the inclusion of extragenital specimens for N. gonorrhoeae AMR surveillance purposes.

[1]  H. Jacquier,et al.  Two cases of multidrug-resistant Neisseria gonorrhoeae related to travel in south-eastern Asia, France, June 2019 , 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[2]  K. Pabbaraju,et al.  Genetic Characterization and Enhanced Surveillance of Ceftriaxone-Resistant Neisseria gonorrhoeae Strain, Alberta, Canada, 2018 , 2019, Emerging infectious diseases.

[3]  C. Fairley,et al.  Trends and Risk Factors for Antimicrobial-Resistant Neisseria gonorrhoeae, Melbourne, Australia, 2007 to 2018 , 2019, Antimicrobial Agents and Chemotherapy.

[4]  Shao-Chun Chen,et al.  Identification of Internationally Disseminated Ceftriaxone-Resistant Neisseria gonorrhoeae Strain FC428, China , 2019, Emerging infectious diseases.

[5]  T. Street,et al.  Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018 , 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[6]  M. Unemo,et al.  Multidrug-resistant Neisseria gonorrhoeae isolate, belonging to the internationally spreading Japanese FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, Ireland, August 2018 , 2018, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[7]  R. Kularatne,et al.  Trends in Neisseria gonorrhoeae Antimicrobial Resistance over a Ten-Year Surveillance Period, Johannesburg, South Africa, 2008–2017 , 2018, Antibiotics.

[8]  M. Unemo,et al.  Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018 , 2018, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[9]  Monica Lahra,et al.  Genetic characterisation of Neisseria gonorrhoeae resistant to both ceftriaxone and azithromycin. , 2018, The Lancet. Infectious diseases.

[10]  W. Demczuk,et al.  Cooperative Recognition of Internationally Disseminated Ceftriaxone-Resistant Neisseria gonorrhoeae Strain , 2018, Emerging infectious diseases.

[11]  A. Katz Ceftriaxone-Resistant Neisseria gonorrhoeae, Canada, 2017 , 2018, Emerging infectious diseases.

[12]  M. Unemo,et al.  Neisseria cinerea with High Ceftriaxone MIC Is a Source of Ceftriaxone and Cefixime Resistance-Mediating penA Sequences in Neisseria gonorrhoeae , 2018, Antimicrobial Agents and Chemotherapy.

[13]  X. Vallès,et al.  Risk factors for antimicrobial-resistant Neisseria gonorrhoeae and characteristics of patients infected with gonorrhea. , 2017, Enfermedades infecciosas y microbiologia clinica.

[14]  Prateek Shrivastava,et al.  World health organization releases global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics , 2018 .

[15]  L. Sánchez-Busó,et al.  The novel 2016 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization. , 2016, The Journal of antimicrobial chemotherapy.

[16]  N. Woodford,et al.  Drifting towards ceftriaxone treatment failure in gonorrhoea: risk factor analysis of data from the Gonococcal Resistance to Antimicrobials Surveillance Programme in England and Wales , 2016, Sexually Transmitted Infections.

[17]  M. Unemo,et al.  Failure of Dual Antimicrobial Therapy in Treatment of Gonorrhea. , 2016, The New England journal of medicine.

[18]  K. Workowski,et al.  Management of Gonorrhea in Adolescents and Adults in the United States. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  D. Lewis Will targeting oropharyngeal gonorrhoea delay the further emergence of drug-resistant Neisseria gonorrhoeae strains? , 2015, Sexually Transmitted Infections.

[20]  A. Amato-Gauci,et al.  Risk Factors for Antimicrobial-Resistant Neisseria gonorrhoeae in Europe , 2014, Sexually transmitted diseases.

[21]  M. Unemo,et al.  Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. , 2013, The Journal of antimicrobial chemotherapy.

[22]  Makoto Ohnishi,et al.  Ceftriaxone-Resistant Neisseria gonorrhoeae, Japan , 2011, Emerging infectious diseases.

[23]  F. Radebe,et al.  Etiology and STI/HIV Coinfections Among Patients With Urethral and Vaginal Discharge Syndromes in South Africa , 2010, Sexually transmitted diseases.

[24]  H. D. de Vries,et al.  Multidrug-resistant Neisseria gonorrhoeae with reduced cefotaxime susceptibility is increasingly common in men who have sex with men, Amsterdam, the Netherlands. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[25]  F. Radebe,et al.  Escalation in the relative prevalence of ciprofloxacin-resistant gonorrhoea among men with urethral discharge in two South African cities: association with HIV seropositivity , 2008, Sexually Transmitted Infections.